Item 2.02 Results of Operations and Financial Condition.

On August 9, 2021, NexImmune, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2021 and providing business highlights. The full text of the press release is incorporated by reference herein and furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

On August 9, 2021 the Company issued a press release announcing its collaboration with Yale University's Department of Immunobiology, which will focus on the use of the Company's direct injection, artificial antigen presenting cells with regards to the regulation of autoimmune diabetes. The full text of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits



Exhibit
  No.       Description

99.1          Press release announcing the Company's financial results for the
            second quarter ended June 30, 2021, dated August 9, 2021.

99.2          Press release announcing the Company's collaboration with Yale
            University's Department of Immunobiology

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document)




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses